Trusted Resources: Education
Scientific literature and patient education texts
Gene Replacement Therapy With Onasemnogene Abeparvovec in Children With Spinal Muscular Atrophy Aged 24 Months or Younger and Bodyweight up to 15 Kg: An Observational Cohort Study
source: The Lancet. Child & Adolescent Health
year: 2022
authors: Weiß C,Ziegler A,Becker LL,Johannsen J,Brennenstuhl H,Schreiber G,Flotats-Bastardas M,Stoltenburg C,Hartmann H,Illsinger S,Denecke J,Pechmann A,Müller-Felber W,Vill K,Blaschek A,Smitka M,van der Stam L,Weiss K,Winter B,Goldhahn K,Plecko B,Horber V,Bernert G,Husain RA,Rauscher C,Trollmann R,Garbade SF,Hahn A,von der Hagen M,Kaindl AM
summary/abstract:Given the novelty of gene replacement therapy with onasemnogene abeparvovec in spinal muscular atrophy, efficacy and safety data are limited, especially for children older than 24 months, those weighing more than 8·5 kg, and those who have received nusinersen. We aimed to provide real-world data on motor function and safety after gene replacement therapy in different patient subgroups.
organization: Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Center for Chronically Sick Children, Charité-Universitätsmedizin Berlin, Berlin, Germany.DOI: 10.1016/S2352-4642(21)00287-X
read more
Related Content
-
Kathrin C. Meyer, PhDKathrin C. Meyer, PhD, studied Cellular ...
-
Patient of the Month: GiannaAfter noticing that her daughter was una...
-
Spinal Muscular Atrophy 2020: SMA Medications for Treatment Updateshttps://www.youtube.com/watch?v=dnSXnvrO...
-
Jerry R. Mendell, MDJerry R. Mendell, MD, is an Attending Ne...
-
Infants With Symptomatic SMA Reach Milestones With Gene TherapyGene replacement therapy with onasemnoge...
-
Spinal Muscular Atrophy Fact SheetWhat is spinal muscular atrophy?Spinal m...
-
SMA Gene Replacement Therapyhttps://www.youtube.com/watch?v=vHbJs8bm...